Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 13/20 | 0.35 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26998294 | 1.00 | ATR (0.39) | ATRATRIPROCK2CGASGRM2 | |
| SCHEMBL26998358 | 0.94 | ATR (0.38) | ATRATRIPROCK2PIK3CA | |
| SCHEMBL26998084 | 0.94 | ATR (0.38) | ATRATRIPROCK2GRM2PIK3CA | |
| SCHEMBL26998060 | 0.89 | ATR (0.48) | ATRATRIPROCK2PIK3CA | |
| SCHEMBL26999180 | 0.89 | ATR (0.38) | ATRATRIPROCK2CGASGRM2 | |
| SCHEMBL26998356 | 0.86 | SCN9A (0.43) | ATRATRIPROCK2GRM2PIK3CA | |
| SCHEMBL26998354 | 0.86 | SCN9A (0.43) | ATRATRIPROCK2GRM2PIK3CA | |
| SCHEMBL26998362 | 0.86 | ATR (0.34) | ATRATRIPROCK2GRM2ROCK1 | |
| SCHEMBL26998353 | 0.85 | ATR (0.36) | ATRATRIPROCK2GRM2ROCK1 | |
| SCHEMBL27001067 | 0.83 | ATR (0.43) | ATRATRIPROCK2ROCK1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | ATR 277/4885ATRIP 734/4885ROCK2 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.